FDA Commissioner Marty Makary announced his resignation on Tuesday, May 12, 2026 [1], ending a brief and tumultuous tenure at the agency [2].

The departure of the agency's top official signals significant friction between the FDA's regulatory approach and the priorities of the current administration. Makary's exit follows a period of instability that has seen multiple high-profile departures from the White House this year [3].

Makary left the White House after meeting with President Donald Trump [4]. The president said Makary "was having some difficulty" [5].

His time at the agency lasted 13 months [1], though some reports describe the term as just one year [6]. This period was characterized by tension with administration officials and health-industry executives. These conflicts centered on Makary's handling of new vaping products, and the abortion drug mifepristone [4].

Industry leaders and political allies expressed frustration with his regulatory strategies. This internal pressure combined with growing dissatisfaction from President Trump to prompt the resignation [4].

Makary is the fourth high-profile member of the Trump administration to depart this year [3]. His resignation caps a tenure that observers described as uneven and difficult [7].

The FDA now faces the task of appointing a new leader to navigate the complex regulatory landscape of pharmaceutical approvals, and public health mandates.

“Marty Makary, M.D., is resigning as FDA commissioner Tuesday, ending a brief but tumultuous tenure.”

The resignation of Marty Makary highlights a deepening rift between the FDA's traditional regulatory framework and the political objectives of the Trump administration. By clashing over high-stakes issues like mifepristone and vaping, Makary became a flashpoint for the struggle to balance medical autonomy with executive policy. His departure suggests the administration may seek a successor more aligned with its specific industry and social goals.